RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment
Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months
ODAC Votes 13:0 For Approving Perjeta
Early Treatment with CMX001 Can Help Prevent CMV Infection
Researchers Identify Mutation Linked to Inherited Risk of ALL
Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia
Avoiding the Hippocampus During Whole-Brain Radiotherapy Can Preserve Memory Function
Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy
Long-term Hormonal Therapy Adds No Additional Benefits
NCI CTEP Approved Trials For the Month of September
FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest
- In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”
- As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - Scaling excellence: How City of Hope is transforming cancer care delivery
